$LNDZF
EVOME MEDICAL TECHNOLOGIES INC.

2022 Q1 Form 10-K Financial Statement

#000106299322013882 Filed on May 31, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2022 2021
Revenue 10.11M cads 18.31M CADs -33.55K CADs
YoY Change -54686.9% -108.39%
Cost Of Revenue $5.573M $12.35M $12.35M
YoY Change 0.0% 61650.0%
Gross Profit $2.888M $5.960M $5.960M
YoY Change 0.0% 1468.42%
Gross Profit Margin 28.56% 32.55%
Selling, General & Admin $2.474M $5.730M $990.0K
YoY Change 478.79% -40.0%
% of Gross Profit 85.66% 96.14% 16.61%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $359.3K $840.0K $0.00
YoY Change -100.0%
% of Gross Profit 12.44% 14.09% 0.0%
Operating Expenses $2.833M $6.580M $990.0K
YoY Change 564.65% -39.63%
Operating Profit $54.94K -$620.0K $4.970M
YoY Change -112.47% -494.44%
Interest Expense $5.786M $5.480M $5.480M
YoY Change 0.0%
% of Operating Profit 10531.54% 110.26%
Other Income/Expense, Net -$1.573M -$3.840M -$3.840M
YoY Change 0.0%
Pretax Income -3.256M cads -4.474M CADs -2.667M CADs
YoY Change 67.71% 97.59%
Income Tax -$103.6K -101.6K CADs 0.000 CADs
% Of Pretax Income
Net Earnings -$1.149M -$4.370M -$2.670M
YoY Change 63.67% 39.06%
Net Earnings / Revenue -11.36% -23.86%
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$22.94K -$100.2K -$78.99K
COMMON SHARES
Basic Shares Outstanding 53.81M
Diluted Shares Outstanding 50.02M

Balance Sheet

Concept 2022 Q1 2022 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.057M $8.060M $7.570M
YoY Change 6.47% -17.63%
Cash & Equivalents 8.057M cads $8.060M $7.080M
Short-Term Investments $0.00 $0.00 $490.0K
Other Short-Term Assets $412.8K $410.0K $5.570M
YoY Change -92.64% 3878.57%
Inventory 4.969M cads $4.970M $4.970M
Prepaid Expenses 412.8K cads
Receivables 6.596M cads $6.600M $0.00
Other Receivables 233.8K cads $0.00 $0.00
Total Short-Term Assets 20.04M cads $20.04M $13.13M
YoY Change 52.63% 34.94%
LONG-TERM ASSETS
Property, Plant & Equipment 1.460M cads $5.400M $5.400M
YoY Change 0.0%
Goodwill 9.833M cads
YoY Change
Intangibles 6.927M cads
YoY Change
Long-Term Investments $485.0K $480.0K $480.0K
YoY Change 0.0%
Other Assets $441.0K
YoY Change
Total Long-Term Assets 22.65M cads $22.64M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets 20.04M cads $20.04M $13.13M
Total Long-Term Assets 22.65M cads $22.64M $0.00
Total Assets 42.68M cads $42.68M $13.13M
YoY Change 225.06% 34.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable 2.863M cads $3.680M $1.050M
YoY Change 496.68% 250.48% 377.27%
Accrued Expenses 816.7K cads $1.372M
YoY Change 43.78%
Deferred Revenue
YoY Change
Short-Term Debt $5.497M $5.500M $0.00
YoY Change
Long-Term Debt Due 174.4K cads $420.0K $420.0K
YoY Change 0.0%
Total Short-Term Liabilities 23.16M cads $23.16M $6.470M
YoY Change 257.96% 2840.91%
LONG-TERM LIABILITIES
Long-Term Debt 681.8K cads $4.620M $0.00
YoY Change
Other Long-Term Liabilities $20.00K
YoY Change 0.0%
Total Long-Term Liabilities 681.8K cads $4.620M $20.00K
YoY Change 23000.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities 23.16M cads $23.16M $6.470M
Total Long-Term Liabilities 681.8K cads $4.620M $20.00K
Total Liabilities 29.53M cads $29.53M $6.490M
YoY Change 355.01% 2721.74%
SHAREHOLDERS EQUITY
Retained Earnings -33.36M cads
YoY Change
Common Stock 38.05M cads
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity 13.15M cads $13.15M $6.640M
YoY Change
Total Liabilities & Shareholders Equity 42.68M cads $42.68M $13.13M
YoY Change 225.06% 34.94%

Cashflow Statement

Concept 2022 Q1 2022 2021
OPERATING ACTIVITIES
Net Income -$1.149M -$4.370M -$2.670M
YoY Change 63.67% 39.06%
Depreciation, Depletion And Amortization $359.3K $840.0K $0.00
YoY Change -100.0%
Cash From Operating Activities -$2.368M -$3.700M -$980.0K
YoY Change 277.55% 653.85%
INVESTING ACTIVITIES
Capital Expenditures -$14.21K -$60.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$461.1K -$4.560M $70.00K
YoY Change -6614.29% -107.78%
Cash From Investing Activities -$475.3K -$4.620M $70.00K
YoY Change -6700.0% -107.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net 4.262M CADs 4.262M CADs 0.000 CADs
YoY Change
Debt Paid & Issued, Net 42.06K cads
YoY Change
Cash From Financing Activities 5.027M 3.940M 5.430M
YoY Change -27.44% 0.0%
NET CHANGE
Cash From Operating Activities -2.368M -3.700M -980.0K
Cash From Investing Activities -475.3K -4.620M 70.00K
Cash From Financing Activities 5.027M 3.940M 5.430M
Net Change In Cash 2.184M -4.380M 4.520M
YoY Change -196.9% -538.83%
FREE CASH FLOW
Cash From Operating Activities -$2.368M -$3.700M -$980.0K
Capital Expenditures -$14.21K -$60.00K $0.00
Free Cash Flow -$2.354M -$3.640M -$980.0K
YoY Change 271.43% 653.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--02-28
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Public Float
EntityPublicFloat
29947333 CAD
CY2022 dei Auditor Name
AuditorName
SRCO Professional Corporation
CY2022 dei Auditor Firm
AuditorFirmId
5828
CY2022 dei Auditor Location
AuditorLocation
Richmond Hill, Ontario, Canada
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
149919 CAD
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18312269 CAD
CY2022 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 CAD
CY2021 us-gaap Impairment Of Investments
ImpairmentOfInvestments
183466 CAD
CY2022 us-gaap Revenues
Revenues
18312269 CAD
CY2021 us-gaap Revenues
Revenues
-33547 CAD
CY2022 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
5520522 CAD
CY2021 sgmd Income Tax Recovery Expense
IncomeTaxRecoveryExpense
0 CAD
CY2022 sgmd Share Issuance Costs From Financing
ShareIssuanceCostsFromFinancing
-660052 CAD
CY2022 sgmd Gain On Share For Debt Settlement
GainOnShareForDebtSettlement
-15538 CAD
CY2021 sgmd Gain On Share For Debt Settlement
GainOnShareForDebtSettlement
0 CAD
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-113639 CAD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 CAD
CY2022 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
5520522 CAD
CY2021 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 CAD
CY2022 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
-918361 CAD
CY2021 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
0 CAD
CY2022 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 CAD
CY2021 us-gaap Impairment Of Investments
ImpairmentOfInvestments
183466 CAD
CY2022 sgmd Increase Decrease In Net Repayment Of Credit Receivables
IncreaseDecreaseInNetRepaymentOfCreditReceivables
0 CAD
CY2021 sgmd Increase Decrease In Net Repayment Of Credit Receivables
IncreaseDecreaseInNetRepaymentOfCreditReceivables
394091 CAD
CY2022 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 CAD
CY2021 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
183466 CAD
CY2022 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
939696 CAD
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 CAD
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4261950 CAD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 CAD
CY2022 sgmd Proceeds From Subscription Receipts
ProceedsFromSubscriptionReceipts
0 CAD
CY2021 sgmd Proceeds From Subscription Receipts
ProceedsFromSubscriptionReceipts
5425374 CAD
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
269954 CAD
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-left:35.95pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="color:#12151a"><i>c)</i> <i>Use of estimates</i></span></span></span></p> <p style="text-indent:35.95pt;text-align:justify"><span style="font-size:10pt;line-height:107%;font-family:Times New Roman, serif;color:rgb(18, 21, 26)">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies to useful lives of non-current assets, impairment of non-current assets, including goodwill and intangible assets, valuation of stock-based compensation, allowance for doubtful accounts, provisions for inventory and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p> </div>
CY2022 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0 CAD
CY2021 us-gaap Impairment Of Investments
ImpairmentOfInvestments
183466 CAD
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
562262 CAD
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15000 CAD
CY2022Q1 sgmd Accounts Payable Accrued Liabilities And Other Liabilities
AccountsPayableAccruedLiabilitiesAndOtherLiabilities
4241658 CAD
CY2021Q1 sgmd Accounts Payable Accrued Liabilities And Other Liabilities
AccountsPayableAccruedLiabilitiesAndOtherLiabilities
1062784 CAD
CY2022 sgmd Unearned Customer Deposits And Revenues
UnearnedCustomerDepositsAndRevenues
426609 CAD
CY2022 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
0.3944 pure
CY2022 sgmd Acquired Operating Leases Noncurrent
AcquiredOperatingLeasesNoncurrent
3842550 CAD
CY2020Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.19
CY2020Q4 sgmd Fair Value Of Stock Options Exercised
FairValueOfStockOptionsExercised
4323 CAD
CY2022 sgmd Acquired Operating Leases
AcquiredOperatingLeases
4109681 CAD
CY2022 sgmd Acquired Operating Leases Current
AcquiredOperatingLeasesCurrent
267131 CAD
CY2021Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2121232
CY2021Q2 us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
2121232
us-gaap Line Of Credit Facility Decrease Forgiveness1
LineOfCreditFacilityDecreaseForgiveness1
918316 CAD
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
13685 CAD
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0033 pure
CY2021Q2 us-gaap Share Price
SharePrice
0.16
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
112617
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
112617
CY2021Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.19
CY2020Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
28154
CY2020Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
28154
CY2020Q4 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5348 CAD
CY2021Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21392 CAD
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
199804
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.83 pure
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
289185 CAD
CY2021Q4 us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
199804
CY2021Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.86
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.7
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.01 pure
CY2021Q4 us-gaap Share Price
SharePrice
0.87
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7749000
CY2022Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7749000
CY2022Q1 us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
7749000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4261950 CAD
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3591369 CAD
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.46
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.92 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
CY2022Q1 us-gaap Share Price
SharePrice
0.52
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
254829 CAD
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.47
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.92 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
CY2022Q1 us-gaap Share Price
SharePrice
0.52
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-101617 CAD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
-0.1084 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0227 pure
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 CAD
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2022Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1755889 CAD
CY2021Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0 CAD
CY2022 sgmd Number Of Warrants Issued
NumberOfWarrantsIssued
11731373
CY2021 sgmd Number Of Warrants Issued
NumberOfWarrantsIssued
0
CY2022 sgmd Number Of Warrants Issued As Part Of Finance Deal
NumberOfWarrantsIssuedAsPartOfFinanceDeal
10070036
CY2022 sgmd Number Of Broker Warrants Issued As Part Of Finance Deal
NumberOfBrokerWarrantsIssuedAsPartOfFinanceDeal
1662337
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
12022 CAD
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 CAD
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-113639 CAD
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 CAD
CY2022 sgmd Income Tax Recovery Expense
IncomeTaxRecoveryExpense
0 CAD
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
496526 CAD
CY2022 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
10107 CAD
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
12022 CAD
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 CAD
CY2022Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
4481137 CAD
CY2021Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2904627 CAD
CY2022Q1 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
507758 CAD
CY2021Q1 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1732555 CAD
CY2022Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4988895 CAD
CY2021Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
4637182 CAD
CY2022Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 CAD
CY2021Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 CAD
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.2535 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.265 pure
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4473636 CAD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2667423 CAD
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1134067 CAD
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2535 pure
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-706866 CAD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.265 pure
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
1287727 CAD
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.2878 pure
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
354687 CAD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.133 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
1508951 CAD
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.3373 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
62994 CAD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.0236 pure
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
-1764228 CAD
CY2022Q1 us-gaap Conversion Of Stock Description
ConversionOfStockDescription
The Class B Units will be non-voting, non-participating units of the Salona Global Buyer that will be exchangeable into Class "A" non-voting ‎Common Shares of Salona Global ("Salona Global Class "A" Shares ") on a one for one basis.

Files In Submission

Name View Source Status
0001062993-22-013882-index-headers.html Edgar Link pending
0001062993-22-013882-index.html Edgar Link pending
0001062993-22-013882.txt Edgar Link pending
0001062993-22-013882-xbrl.zip Edgar Link pending
exhibit21-1.htm Edgar Link pending
exhibit23-1.htm Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit31-2.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
exhibit32-2.htm Edgar Link pending
exhibit99.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10k.htm Edgar Link pending
form10kxz001.jpg Edgar Link pending
form10k_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmd-20220228.xsd Edgar Link pending
sgmd-20220228_cal.xml Edgar Link unprocessable
sgmd-20220228_def.xml Edgar Link unprocessable
sgmd-20220228_lab.xml Edgar Link unprocessable
sgmd-20220228_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending